120,350 Denali Therapeutics Inc. $DNLI Shares Sold by Candriam S.C.A.

Posted by Francis Steltz on Nov 9th, 2026

Candriam S.C.A. lowered its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 10.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,069,536 shares of the company’s stock after selling 120,350 shares during the period. Candriam S.C.A.’s holdings in Denali Therapeutics were worth $22,188,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of DNLI. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Denali Therapeutics during the 2nd quarter worth approximately $26,000. Global Retirement Partners LLC acquired a new position in shares of Denali Therapeutics in the 2nd quarter valued at approximately $28,000. Nykredit A S acquired a new position in shares of Denali Therapeutics in the 2nd quarter valued at approximately $38,000. Allworth Financial LP purchased a new position in shares of Denali Therapeutics during the 2nd quarter valued at approximately $47,000. Finally, Manchester Capital Management LLC boosted its stake in shares of Denali Therapeutics by 5,505.6% during the 3rd quarter. Manchester Capital Management LLC now owns 2,018 shares of the company’s stock valued at $42,000 after buying an additional 1,982 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. HC Wainwright began coverage on shares of Denali Therapeutics in a research report on Wednesday, November 4th. They set a “strong-buy” rating for the company. Morgan Stanley lifted their price target on shares of Denali Therapeutics from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. began coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They issued an “overweight” rating and a $29.00 price target on the stock. B. Riley Financial upped their price target on shares of Denali Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.15.

Read Our Latest Report on Denali Therapeutics

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of Denali Therapeutics stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the transaction, the insider owned 281,763 shares of the company’s stock, valued at $7,063,798.41. The trade was a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 9.70% of the stock is owned by company insiders.

Key Headlines Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

Positive Sentiment: Denali’s third-quarter results beat expectations: EPS was $0.37 versus the consensus estimate of a $0.27 loss, and revenue was $17.78 million versus a $12.67 million estimate. Denali Therapeutics earnings beat and valuation article
Positive Sentiment: Commercial momentum and potential catalysts may be lifting sentiment: a report cited nearly fivefold growth in Avlayah sales, broader reimbursement coverage, and multiple upcoming pipeline catalysts. Shares were reported up 7.8% after the earnings release. Zacks report on Denali post-earnings performance
Positive Sentiment: HC Wainwright initiated coverage with a “Strong Buy” rating, providing a new bullish analyst view. HC Wainwright stock recommendations
Neutral Sentiment: HC Wainwright’s forecasts show losses continuing in coming years, though its estimates narrow to a $0.14-per-share loss by 2030. The longer-term outlook is therefore still dependent on commercial growth and pipeline progress.
Neutral Sentiment: A separate report put Denali’s valuation back in focus after the earnings-driven move, suggesting investors may weigh the improved results against the stock’s valuation. Denali earnings and valuation article

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI opened at $20.07 on Monday. The company has a quick ratio of 5.94, a current ratio of 6.21 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $20.16 and its two-hundred day moving average price is $21.27. Denali Therapeutics Inc. has a 52-week low of $13.75 and a 52-week high of $27.30. The stock has a market capitalization of $3.22 billion, a P/E ratio of -11.60 and a beta of 1.08.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported $0.37 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.64. The firm had revenue of $17.78 million during the quarter, compared to analyst estimates of $12.67 million. During the same quarter in the previous year, the business posted ($0.74) EPS. On average, analysts anticipate that Denali Therapeutics Inc. will post -1.94 earnings per share for the current fiscal year.

Denali Therapeutics Company Profile

(Free Report)

Denali Therapeutics is a biotechnology company focused on developing medicines for neurodegenerative diseases and other disorders involving the nervous system. Founded in 2015, the company is headquartered in South San Francisco, California.

Its research and development programs target conditions including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders. Denali’s portfolio includes investigational drug candidates that aim to address underlying disease processes, as well as its TransportVehicle platform, designed to help therapeutic molecules cross the blood-brain barrier.

Denali was co-founded by Ryan Watts, who serves as the company’s chief executive officer.